Literature DB >> 8557829

Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls.

I Lundberg1, J M Brengman, A G Engel.   

Abstract

We investigated the profiles of cytokine mRNA expression in muscle in 15 cases of inflammatory myopathy (IM) (5 each of polymyositis, inclusion body myositis, and dermatomyositis) and in 10 controls (5 of Duchenne dystrophy and 5 non-weak subjects). Expressions of the predominantly T cell-derived cytokines (interleukin (IL)-2, IL-4, IL-5, and interferon-gamma (IFN-gamma), of the predominantly macrophage-derived cytokines (IL-1, IL-6, and tumor necrosis factor-alpha (TNF-alpha)), as well as cytokines that can be of either T cell or macrophage origin (granulocyte-macrophage colony stimulating factor (GM-CSF) and transforming growth factor beta 1 (TGF-beta 1) and TGF-beta 2), were monitored by the reverse transcriptase-PCR method. The expression of T cell cytokine mRNAs for IL-2, IL-5, and IFN-gamma was generally weak or inconsistent. IL-4 mRNA expression was consistently moderate to strong in polymyositis but generally weak or absent in the other IMs. The expression of macrophage cytokine mRNAs for IL-1 alpha and IL-1 beta was weak or absent in all cases. Variable TNF-alpha mRNA expression was observed in 12 of 15 IM cases and faint or weak expression in 5 of 10 controls. Very strong GM-CSF expression was detected, but only on boosted PCR, in 12 of 15 cases of IM but in none of the controls. IL-6 was expressed only weakly or inconsistently. In contrast to the variable expression of several of the above mentioned cytokine mRNAs, all IM specimens strongly expressed TGF-beta 1 mRNA and 12 of 15 strongly expressed TGF-beta 2 mRNA. Thus, with the exception of IL-4 expression in polymyositis, a similar pattern of cytokine mRNA expression exists in the different types of IMs. Moreover, this pattern resembles that detected in non-weak and DD controls, although expression is generally weaker in the non-weak controls. The findings suggest that in IM muscle a sustained secretion of cytokines by T cells or of IL-1 by macrophages is not a prerequisite for operation of the immune effector response and that muscle may not be the site of ongoing sensitization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557829     DOI: 10.1016/0165-5728(95)00122-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  47 in total

1.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.

Authors:  K Nagaraju; N Raben; L Loeffler; T Parker; P J Rochon; E Lee; C Danning; R Wada; C Thompson; G Bahtiyar; J Craft; R Hooft Van Huijsduijnen; P Plotz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

3.  Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle.

Authors:  Katherine E Wardrop; Janice A Dominov
Journal:  J Histochem Cytochem       Date:  2011-02       Impact factor: 2.479

4.  X-linked vacuolated myopathy : TNF-alpha and IFN-gamma expression in muscle fibers with MHC class I on sarcolemma.

Authors:  K Rouger; J P Louboutin; M Villanova; Y Cherel; M Fardeau
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

5.  Effect of IL-1β, TNF-α and IGF-1 on trans-endothelial passage of synthetic vectors through an in vitro vascular endothelial barrier of striated muscle.

Authors:  J P Gomez; C Gonçalves; C Pichon; P Midoux
Journal:  Gene Ther       Date:  2017-05-15       Impact factor: 5.250

6.  Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand.

Authors:  Peter Szodoray; Philip Alex; Nicholas Knowlton; Michael Centola; Igor Dozmorov; Istvan Csipo; Annamaria T Nagy; Tamas Constantin; Andrea Ponyi; Britt Nakken; Katalin Danko
Journal:  Rheumatology (Oxford)       Date:  2010-06-29       Impact factor: 7.580

7.  Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

Authors:  S Armando Villalta; Hal X Nguyen; Bo Deng; Tomomi Gotoh; James G Tidball
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

Review 8.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

Review 9.  A critical role for immature muscle precursors in myositis.

Authors:  Anne Tournadre; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2013-03-12       Impact factor: 20.543

10.  Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis.

Authors:  Geun-Tae Kim; Mi-La Cho; Young-Eun Park; Wan Hee Yoo; Jung-Hee Kim; Hye-Jwa Oh; Dae-Sung Kim; Seung-Hoon Baek; Sun-Hee Lee; Jun-Hee Lee; Ho-Youn Kim; Sung-Il Kim
Journal:  Clin Rheumatol       Date:  2009-12-02       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.